nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—EGFR—pharynx cancer	0.875	1	CbGaD
Afatinib—ERBB2—mouth—pharynx cancer	0.00358	0.0674	CbGeAlD
Afatinib—ERBB2—neck—pharynx cancer	0.00306	0.0576	CbGeAlD
Afatinib—Vandetanib—EGFR—pharynx cancer	0.00296	0.513	CrCbGaD
Afatinib—Gefitinib—EGFR—pharynx cancer	0.00281	0.487	CrCbGaD
Afatinib—PHKG2—brainstem—pharynx cancer	0.0026	0.049	CbGeAlD
Afatinib—ERBB2—saliva-secreting gland—pharynx cancer	0.00239	0.0449	CbGeAlD
Afatinib—ERBB4—saliva-secreting gland—pharynx cancer	0.00239	0.0449	CbGeAlD
Afatinib—BLK—lymphoid tissue—pharynx cancer	0.00234	0.044	CbGeAlD
Afatinib—ERBB4—brainstem—pharynx cancer	0.00234	0.044	CbGeAlD
Afatinib—DYRK1A—brainstem—pharynx cancer	0.00225	0.0424	CbGeAlD
Afatinib—ERBB2—epithelium—pharynx cancer	0.00208	0.0392	CbGeAlD
Afatinib—ERBB4—epithelium—pharynx cancer	0.00208	0.0392	CbGeAlD
Afatinib—ERBB2—lymphoid tissue—pharynx cancer	0.00161	0.0302	CbGeAlD
Afatinib—DYRK1A—lymphoid tissue—pharynx cancer	0.00155	0.0291	CbGeAlD
Afatinib—EPHA6—head—pharynx cancer	0.00149	0.0281	CbGeAlD
Afatinib—ERBB4—spinal cord—pharynx cancer	0.00146	0.0274	CbGeAlD
Afatinib—PHKG2—head—pharynx cancer	0.00144	0.0271	CbGeAlD
Afatinib—LCK—trachea—pharynx cancer	0.00134	0.0253	CbGeAlD
Afatinib—BLK—lymph node—pharynx cancer	0.00132	0.0249	CbGeAlD
Afatinib—ERBB2—head—pharynx cancer	0.00129	0.0243	CbGeAlD
Afatinib—ERBB4—head—pharynx cancer	0.00129	0.0243	CbGeAlD
Afatinib—DYRK1A—head—pharynx cancer	0.00125	0.0234	CbGeAlD
Afatinib—ABL1—parotid gland—pharynx cancer	0.00105	0.0197	CbGeAlD
Afatinib—PHKG2—lymph node—pharynx cancer	0.00101	0.0189	CbGeAlD
Afatinib—ABL1—saliva-secreting gland—pharynx cancer	0.001	0.0188	CbGeAlD
Afatinib—ABL1—brainstem—pharynx cancer	0.000981	0.0184	CbGeAlD
Afatinib—ERBB2—lymph node—pharynx cancer	0.000906	0.017	CbGeAlD
Afatinib—DYRK1A—lymph node—pharynx cancer	0.000872	0.0164	CbGeAlD
Afatinib—ABL1—trachea—pharynx cancer	0.000772	0.0145	CbGeAlD
Afatinib—EGFR—lymph node—pharynx cancer	0.000768	0.0144	CbGeAlD
Afatinib—IRAK1—lymph node—pharynx cancer	0.000678	0.0127	CbGeAlD
Afatinib—ABL1—lymphoid tissue—pharynx cancer	0.000673	0.0126	CbGeAlD
Afatinib—LCK—lymph node—pharynx cancer	0.000661	0.0124	CbGeAlD
Afatinib—ABCG2—parotid gland—pharynx cancer	0.000659	0.0124	CbGeAlD
Afatinib—ABCG2—saliva-secreting gland—pharynx cancer	0.000631	0.0119	CbGeAlD
Afatinib—ABL1—spinal cord—pharynx cancer	0.00061	0.0115	CbGeAlD
Afatinib—ABL1—head—pharynx cancer	0.000542	0.0102	CbGeAlD
Afatinib—ERBB2—a6b1 and a6b4 Integrin signaling—EGFR—pharynx cancer	0.000496	0.00746	CbGpPWpGaD
Afatinib—ERBB2—Validated targets of C-MYC transcriptional repression—CCND1—pharynx cancer	0.000483	0.00727	CbGpPWpGaD
Afatinib—ERBB2—B Cell Activation—CD79A—pharynx cancer	0.000471	0.00709	CbGpPWpGaD
Afatinib—ABL1—TP53 Network—TP53—pharynx cancer	0.000469	0.00706	CbGpPWpGaD
Afatinib—ERBB4—B Cell Activation—CD79A—pharynx cancer	0.000464	0.00698	CbGpPWpGaD
Afatinib—ABL1—Posttranslational regulation of adherens junction stability and dissassembly—CDH1—pharynx cancer	0.000455	0.00685	CbGpPWpGaD
Afatinib—BLK—B Cell Activation—CD79A—pharynx cancer	0.000446	0.00671	CbGpPWpGaD
Afatinib—EGFR—Stabilization and expansion of the E-cadherin adherens junction—CDH1—pharynx cancer	0.000433	0.00652	CbGpPWpGaD
Afatinib—PHKG2—Metabolism—CNDP2—pharynx cancer	0.000432	0.00651	CbGpPWpGaD
Afatinib—ERBB2—ErbB Signaling Pathway—EGFR—pharynx cancer	0.000428	0.00645	CbGpPWpGaD
Afatinib—ERBB4—ErbB Signaling Pathway—EGFR—pharynx cancer	0.000422	0.00635	CbGpPWpGaD
Afatinib—ERBB2—Leptin signaling pathway—CCND1—pharynx cancer	0.00042	0.00632	CbGpPWpGaD
Afatinib—BLK—Signaling events mediated by PTP1B—EGFR—pharynx cancer	0.000418	0.0063	CbGpPWpGaD
Afatinib—EGFR—Bladder Cancer—CCND1—pharynx cancer	0.000411	0.00619	CbGpPWpGaD
Afatinib—EGFR—a6b1 and a6b4 Integrin signaling—CDH1—pharynx cancer	0.00041	0.00617	CbGpPWpGaD
Afatinib—ABL1—Pathogenic Escherichia coli infection—CDH1—pharynx cancer	0.000408	0.00615	CbGpPWpGaD
Afatinib—BLK—Thromboxane A2 receptor signaling—EGFR—pharynx cancer	0.000394	0.00594	CbGpPWpGaD
Afatinib—PHKG2—Disease—B4GALT5—pharynx cancer	0.000391	0.00589	CbGpPWpGaD
Afatinib—PHKG2—Metabolism—ADH7—pharynx cancer	0.000391	0.00589	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways in Glioblastoma—CCND1—pharynx cancer	0.000391	0.00588	CbGpPWpGaD
Afatinib—EGFR—Posttranslational regulation of adherens junction stability and dissassembly—CDH1—pharynx cancer	0.000389	0.00586	CbGpPWpGaD
Afatinib—ABCG2—spinal cord—pharynx cancer	0.000385	0.00723	CbGeAlD
Afatinib—LCK—B Cell Receptor Signaling Pathway—CD79A—pharynx cancer	0.000383	0.00577	CbGpPWpGaD
Afatinib—ABL1—lymph node—pharynx cancer	0.00038	0.00714	CbGeAlD
Afatinib—ERBB2—Rac1/Pak1/p38/MMP-2 pathway—EGFR—pharynx cancer	0.00036	0.00543	CbGpPWpGaD
Afatinib—ERBB2—ErbB Signaling Pathway—TP53—pharynx cancer	0.00036	0.00541	CbGpPWpGaD
Afatinib—ERBB4—ErbB Signaling Pathway—TP53—pharynx cancer	0.000354	0.00533	CbGpPWpGaD
Afatinib—PHKG2—Metabolism—ADH1B—pharynx cancer	0.000343	0.00516	CbGpPWpGaD
Afatinib—PHKG2—Metabolism—B4GALT5—pharynx cancer	0.000328	0.00493	CbGpPWpGaD
Afatinib—ERBB2—DNA Damage Response (only ATM dependent)—CCND1—pharynx cancer	0.000311	0.00469	CbGpPWpGaD
Afatinib—ABL1—ErbB Signaling Pathway—CCND1—pharynx cancer	0.000309	0.00465	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways in Glioblastoma—EGFR—pharynx cancer	0.000307	0.00462	CbGpPWpGaD
Afatinib—ERBB2—Rac1/Pak1/p38/MMP-2 pathway—TP53—pharynx cancer	0.000303	0.00456	CbGpPWpGaD
Afatinib—ERBB2—Constitutive PI3K/AKT Signaling in Cancer—EGFR—pharynx cancer	0.000295	0.00444	CbGpPWpGaD
Afatinib—ERBB4—Constitutive PI3K/AKT Signaling in Cancer—EGFR—pharynx cancer	0.000291	0.00438	CbGpPWpGaD
Afatinib—ABL1—Neurotrophic factor-mediated Trk receptor signaling—CCND1—pharynx cancer	0.00028	0.00422	CbGpPWpGaD
Afatinib—ABCB1—epithelium—pharynx cancer	0.000272	0.00511	CbGeAlD
Afatinib—EGFR—Bladder Cancer—TP53—pharynx cancer	0.000271	0.00408	CbGpPWpGaD
Afatinib—EGFR—Gastric Cancer Network 2—TP53—pharynx cancer	0.000271	0.00408	CbGpPWpGaD
Afatinib—ABL1—Posttranslational regulation of adherens junction stability and dissassembly—EGFR—pharynx cancer	0.000266	0.00401	CbGpPWpGaD
Afatinib—ERBB2—PI-3K cascade—EGFR—pharynx cancer	0.000266	0.004	CbGpPWpGaD
Afatinib—EGFR—ErbB Signaling Pathway—CCND1—pharynx cancer	0.000264	0.00397	CbGpPWpGaD
Afatinib—ABL1—Regulation of retinoblastoma protein—CCND1—pharynx cancer	0.000263	0.00396	CbGpPWpGaD
Afatinib—ERBB4—PI-3K cascade—EGFR—pharynx cancer	0.000262	0.00394	CbGpPWpGaD
Afatinib—ERBB2—PI3K/AKT activation—EGFR—pharynx cancer	0.00026	0.00391	CbGpPWpGaD
Afatinib—ABL1—ATM Signaling Pathway—TP53—pharynx cancer	0.000259	0.00389	CbGpPWpGaD
Afatinib—ERBB2—GAB1 signalosome—EGFR—pharynx cancer	0.000258	0.00388	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways in Glioblastoma—TP53—pharynx cancer	0.000257	0.00388	CbGpPWpGaD
Afatinib—ABL1—DNA Damage Response—CCND1—pharynx cancer	0.000257	0.00387	CbGpPWpGaD
Afatinib—ABL1—Regulation of Telomerase—CCND1—pharynx cancer	0.000257	0.00387	CbGpPWpGaD
Afatinib—ERBB4—PI3K/AKT activation—EGFR—pharynx cancer	0.000256	0.00385	CbGpPWpGaD
Afatinib—ERBB4—GAB1 signalosome—EGFR—pharynx cancer	0.000254	0.00382	CbGpPWpGaD
Afatinib—DYRK1A—Circadian rythm related genes—TP53—pharynx cancer	0.000253	0.00382	CbGpPWpGaD
Afatinib—ERBB2—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—pharynx cancer	0.000252	0.00379	CbGpPWpGaD
Afatinib—ABL1—Cell Cycle—CDH1—pharynx cancer	0.000249	0.00375	CbGpPWpGaD
Afatinib—ABL1—miRNA Regulation of DNA Damage Response—CCND1—pharynx cancer	0.000248	0.00374	CbGpPWpGaD
Afatinib—ERBB4—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—pharynx cancer	0.000248	0.00373	CbGpPWpGaD
Afatinib—ABL1—ErbB Signaling Pathway—EGFR—pharynx cancer	0.000242	0.00365	CbGpPWpGaD
Afatinib—ABCG2—Fluoropyrimidine Activity—TP53—pharynx cancer	0.000241	0.00362	CbGpPWpGaD
Afatinib—ABCB1—trachea—pharynx cancer	0.00024	0.00452	CbGeAlD
Afatinib—ABCG2—lymph node—pharynx cancer	0.000239	0.0045	CbGeAlD
Afatinib—LCK—Notch Signaling Pathway—CCND1—pharynx cancer	0.000231	0.00347	CbGpPWpGaD
Afatinib—EGFR—B Cell Activation—CD79A—pharynx cancer	0.000228	0.00343	CbGpPWpGaD
Afatinib—BLK—Apoptosis Modulation and Signaling—TP53—pharynx cancer	0.000224	0.00338	CbGpPWpGaD
Afatinib—EGFR—Regulation of Telomerase—CCND1—pharynx cancer	0.000219	0.0033	CbGpPWpGaD
Afatinib—LCK—B Cell Activation—CD79A—pharynx cancer	0.000219	0.0033	CbGpPWpGaD
Afatinib—IRAK1—p75(NTR)-mediated signaling—TP53—pharynx cancer	0.000214	0.00322	CbGpPWpGaD
Afatinib—ABL1—Retinoblastoma (RB) in Cancer—CCND1—pharynx cancer	0.000211	0.00318	CbGpPWpGaD
Afatinib—ABCB1—lymphoid tissue—pharynx cancer	0.000209	0.00393	CbGeAlD
Afatinib—LCK—Signaling events mediated by PTP1B—EGFR—pharynx cancer	0.000206	0.0031	CbGpPWpGaD
Afatinib—ERBB2—DNA Damage Response (only ATM dependent)—TP53—pharynx cancer	0.000205	0.00309	CbGpPWpGaD
Afatinib—ABL1—ErbB Signaling Pathway—TP53—pharynx cancer	0.000203	0.00306	CbGpPWpGaD
Afatinib—ABL1—Regulation of Telomerase—EGFR—pharynx cancer	0.000201	0.00303	CbGpPWpGaD
Afatinib—ERBB2—Focal Adhesion—CCND1—pharynx cancer	0.0002	0.003	CbGpPWpGaD
Afatinib—ERBB2—Signaling by SCF-KIT—EGFR—pharynx cancer	0.000199	0.00299	CbGpPWpGaD
Afatinib—ERBB2—Integrated Pancreatic Cancer Pathway—CCND1—pharynx cancer	0.000199	0.00299	CbGpPWpGaD
Afatinib—ERBB4—Signaling by SCF-KIT—EGFR—pharynx cancer	0.000196	0.00295	CbGpPWpGaD
Afatinib—DYRK1A—Cell Cycle, Mitotic—CCND1—pharynx cancer	0.000194	0.00292	CbGpPWpGaD
Afatinib—ERBB2—Disease—B4GALT5—pharynx cancer	0.000194	0.00292	CbGpPWpGaD
Afatinib—LCK—Thromboxane A2 receptor signaling—EGFR—pharynx cancer	0.000194	0.00292	CbGpPWpGaD
Afatinib—ERBB4—Disease—B4GALT5—pharynx cancer	0.000191	0.00288	CbGpPWpGaD
Afatinib—ERBB2—Downstream signaling of activated FGFR—EGFR—pharynx cancer	0.00019	0.00286	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—CD79A—pharynx cancer	0.00019	0.00286	CbGpPWpGaD
Afatinib—ABCB1—spinal cord—pharynx cancer	0.00019	0.00357	CbGeAlD
Afatinib—ABL1—p53 pathway—TP53—pharynx cancer	0.00019	0.00285	CbGpPWpGaD
Afatinib—BLK—Focal Adhesion—CCND1—pharynx cancer	0.000189	0.00285	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways in Glioblastoma—CCND1—pharynx cancer	0.000189	0.00284	CbGpPWpGaD
Afatinib—LCK—SHP2 signaling—EGFR—pharynx cancer	0.000188	0.00284	CbGpPWpGaD
Afatinib—ERBB4—Downstream signaling of activated FGFR—EGFR—pharynx cancer	0.000187	0.00282	CbGpPWpGaD
Afatinib—ERBB2—Signaling by ERBB4—EGFR—pharynx cancer	0.000187	0.00282	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—CD79A—pharynx cancer	0.000187	0.00281	CbGpPWpGaD
Afatinib—ERBB4—Signaling by ERBB4—EGFR—pharynx cancer	0.000184	0.00278	CbGpPWpGaD
Afatinib—ABL1—Integrated Breast Cancer Pathway—CDH1—pharynx cancer	0.000182	0.00274	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—CD79A—pharynx cancer	0.00018	0.00271	CbGpPWpGaD
Afatinib—ERBB2—Downstream signal transduction—EGFR—pharynx cancer	0.000179	0.00269	CbGpPWpGaD
Afatinib—ERBB2—Signaling by FGFR—EGFR—pharynx cancer	0.000178	0.00268	CbGpPWpGaD
Afatinib—ERBB2—EGF/EGFR Signaling Pathway—EGFR—pharynx cancer	0.000178	0.00268	CbGpPWpGaD
Afatinib—ERBB2—Signaling by ERBB2—EGFR—pharynx cancer	0.000177	0.00266	CbGpPWpGaD
Afatinib—EGFR—Androgen receptor signaling pathway—CCND1—pharynx cancer	0.000177	0.00266	CbGpPWpGaD
Afatinib—ERBB2—DAP12 signaling—EGFR—pharynx cancer	0.000176	0.00265	CbGpPWpGaD
Afatinib—ABL1—DNA Damage Response (only ATM dependent)—CCND1—pharynx cancer	0.000176	0.00265	CbGpPWpGaD
Afatinib—ERBB4—Downstream signal transduction—EGFR—pharynx cancer	0.000176	0.00265	CbGpPWpGaD
Afatinib—ERBB4—Signaling by FGFR—EGFR—pharynx cancer	0.000175	0.00264	CbGpPWpGaD
Afatinib—ERBB4—Signaling by ERBB2—EGFR—pharynx cancer	0.000174	0.00262	CbGpPWpGaD
Afatinib—EGFR—ErbB Signaling Pathway—TP53—pharynx cancer	0.000174	0.00262	CbGpPWpGaD
Afatinib—ERBB2—Downstream signaling events of B Cell Receptor (BCR)—EGFR—pharynx cancer	0.000174	0.00261	CbGpPWpGaD
Afatinib—DYRK1A—Cell Cycle—CCND1—pharynx cancer	0.000173	0.00261	CbGpPWpGaD
Afatinib—ERBB4—DAP12 signaling—EGFR—pharynx cancer	0.000173	0.00261	CbGpPWpGaD
Afatinib—IRAK1—Apoptosis Modulation and Signaling—TP53—pharynx cancer	0.000171	0.00258	CbGpPWpGaD
Afatinib—ERBB4—Downstream signaling events of B Cell Receptor (BCR)—EGFR—pharynx cancer	0.000171	0.00257	CbGpPWpGaD
Afatinib—ABL1—DNA Damage Response—TP53—pharynx cancer	0.000169	0.00255	CbGpPWpGaD
Afatinib—ABCB1—head—pharynx cancer	0.000169	0.00317	CbGeAlD
Afatinib—ERBB2—Fc epsilon receptor (FCERI) signaling—EGFR—pharynx cancer	0.000166	0.00249	CbGpPWpGaD
Afatinib—ERBB2—Signaling by FGFR in disease—EGFR—pharynx cancer	0.000166	0.00249	CbGpPWpGaD
Afatinib—ERBB2—DAP12 interactions—EGFR—pharynx cancer	0.000166	0.00249	CbGpPWpGaD
Afatinib—ERBB2—Signaling by EGFR—EGFR—pharynx cancer	0.000164	0.00247	CbGpPWpGaD
Afatinib—ABL1—miRNA Regulation of DNA Damage Response—TP53—pharynx cancer	0.000163	0.00246	CbGpPWpGaD
Afatinib—ERBB4—DAP12 interactions—EGFR—pharynx cancer	0.000163	0.00246	CbGpPWpGaD
Afatinib—ERBB4—Fc epsilon receptor (FCERI) signaling—EGFR—pharynx cancer	0.000163	0.00246	CbGpPWpGaD
Afatinib—ERBB4—Signaling by FGFR in disease—EGFR—pharynx cancer	0.000163	0.00246	CbGpPWpGaD
Afatinib—ERBB2—Signaling by EGFR in Cancer—EGFR—pharynx cancer	0.000163	0.00245	CbGpPWpGaD
Afatinib—ERBB2—Signaling by PDGF—EGFR—pharynx cancer	0.000162	0.00244	CbGpPWpGaD
Afatinib—ERBB4—Signaling by EGFR—EGFR—pharynx cancer	0.000162	0.00244	CbGpPWpGaD
Afatinib—ERBB4—Signaling by EGFR in Cancer—EGFR—pharynx cancer	0.00016	0.00241	CbGpPWpGaD
Afatinib—ERBB4—Signaling by PDGF—EGFR—pharynx cancer	0.00016	0.0024	CbGpPWpGaD
Afatinib—ERBB2—Focal Adhesion—EGFR—pharynx cancer	0.000157	0.00236	CbGpPWpGaD
Afatinib—ERBB2—Integrated Pancreatic Cancer Pathway—EGFR—pharynx cancer	0.000156	0.00235	CbGpPWpGaD
Afatinib—EGFR—Integrated Breast Cancer Pathway—CDH1—pharynx cancer	0.000156	0.00234	CbGpPWpGaD
Afatinib—ERBB2—B Cell Activation—EGFR—pharynx cancer	0.000153	0.00231	CbGpPWpGaD
Afatinib—ERBB4—B Cell Activation—EGFR—pharynx cancer	0.000151	0.00227	CbGpPWpGaD
Afatinib—BLK—Focal Adhesion—EGFR—pharynx cancer	0.000148	0.00223	CbGpPWpGaD
Afatinib—ERBB2—NGF signalling via TRKA from the plasma membrane—EGFR—pharynx cancer	0.000147	0.00221	CbGpPWpGaD
Afatinib—EGFR—Rac1/Pak1/p38/MMP-2 pathway—TP53—pharynx cancer	0.000146	0.0022	CbGpPWpGaD
Afatinib—BLK—B Cell Activation—EGFR—pharynx cancer	0.000145	0.00219	CbGpPWpGaD
Afatinib—ERBB4—NGF signalling via TRKA from the plasma membrane—EGFR—pharynx cancer	0.000145	0.00218	CbGpPWpGaD
Afatinib—EGFR—Spinal Cord Injury—CCND1—pharynx cancer	0.000141	0.00213	CbGpPWpGaD
Afatinib—ABL1—Retinoblastoma (RB) in Cancer—TP53—pharynx cancer	0.000139	0.00209	CbGpPWpGaD
Afatinib—EPHA6—Axon guidance—EGFR—pharynx cancer	0.000138	0.00208	CbGpPWpGaD
Afatinib—LCK—Constitutive PI3K/AKT Signaling in Cancer—EGFR—pharynx cancer	0.000138	0.00207	CbGpPWpGaD
Afatinib—ABL1—Integrated Breast Cancer Pathway—CCND1—pharynx cancer	0.000136	0.00204	CbGpPWpGaD
Afatinib—ERBB2—Integrated Pancreatic Cancer Pathway—TP53—pharynx cancer	0.000131	0.00197	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways in Glioblastoma—TP53—pharynx cancer	0.000124	0.00187	CbGpPWpGaD
Afatinib—LCK—PI-3K cascade—EGFR—pharynx cancer	0.000124	0.00187	CbGpPWpGaD
Afatinib—ABL1—Cell Cycle—TP53—pharynx cancer	0.000122	0.00184	CbGpPWpGaD
Afatinib—LCK—PI3K/AKT activation—EGFR—pharynx cancer	0.000121	0.00182	CbGpPWpGaD
Afatinib—LCK—GAB1 signalosome—EGFR—pharynx cancer	0.00012	0.00181	CbGpPWpGaD
Afatinib—ABCB1—lymph node—pharynx cancer	0.000118	0.00222	CbGeAlD
Afatinib—LCK—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—pharynx cancer	0.000117	0.00176	CbGpPWpGaD
Afatinib—ABL1—DNA Damage Response (only ATM dependent)—TP53—pharynx cancer	0.000116	0.00175	CbGpPWpGaD
Afatinib—EGFR—Integrated Breast Cancer Pathway—CCND1—pharynx cancer	0.000116	0.00175	CbGpPWpGaD
Afatinib—ERBB2—Immune System—CD79A—pharynx cancer	0.000115	0.00173	CbGpPWpGaD
Afatinib—DYRK1A—Cell Cycle—TP53—pharynx cancer	0.000114	0.00172	CbGpPWpGaD
Afatinib—ERBB4—Immune System—CD79A—pharynx cancer	0.000113	0.00171	CbGpPWpGaD
Afatinib—ERBB2—Signaling by NGF—EGFR—pharynx cancer	0.000113	0.0017	CbGpPWpGaD
Afatinib—ABL1—Integrated Pancreatic Cancer Pathway—CCND1—pharynx cancer	0.000112	0.00169	CbGpPWpGaD
Afatinib—ERBB4—Signaling by NGF—EGFR—pharynx cancer	0.000111	0.00167	CbGpPWpGaD
Afatinib—BLK—Immune System—CD79A—pharynx cancer	0.000109	0.00164	CbGpPWpGaD
Afatinib—ABL1—Integrated Breast Cancer Pathway—EGFR—pharynx cancer	0.000106	0.0016	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—CDH1—pharynx cancer	0.000106	0.00159	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—CDH1—pharynx cancer	0.000104	0.00157	CbGpPWpGaD
Afatinib—ERBB2—Axon guidance—EGFR—pharynx cancer	0.000102	0.00154	CbGpPWpGaD
Afatinib—ABL1—EGF/EGFR Signaling Pathway—EGFR—pharynx cancer	0.000101	0.00151	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—CDH1—pharynx cancer	0.0001	0.00151	CbGpPWpGaD
Afatinib—EPHA6—Developmental Biology—EGFR—pharynx cancer	9.85e-05	0.00148	CbGpPWpGaD
Afatinib—ABL1—Factors involved in megakaryocyte development and platelet production—TP53—pharynx cancer	9.72e-05	0.00146	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—CNDP2—pharynx cancer	9.67e-05	0.00146	CbGpPWpGaD
Afatinib—EGFR—Focal Adhesion—CCND1—pharynx cancer	9.65e-05	0.00145	CbGpPWpGaD
Afatinib—EGFR—Integrated Pancreatic Cancer Pathway—CCND1—pharynx cancer	9.61e-05	0.00145	CbGpPWpGaD
Afatinib—EGFR—Disease—B4GALT5—pharynx cancer	9.38e-05	0.00141	CbGpPWpGaD
Afatinib—EGFR—Spinal Cord Injury—TP53—pharynx cancer	9.3e-05	0.0014	CbGpPWpGaD
Afatinib—LCK—Signaling by SCF-KIT—EGFR—pharynx cancer	9.26e-05	0.00139	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—CD79A—pharynx cancer	9.17e-05	0.00138	CbGpPWpGaD
Afatinib—LCK—Disease—B4GALT5—pharynx cancer	9.04e-05	0.00136	CbGpPWpGaD
Afatinib—ABL1—Integrated Breast Cancer Pathway—TP53—pharynx cancer	8.94e-05	0.00135	CbGpPWpGaD
Afatinib—LCK—Downstream signaling of activated FGFR—EGFR—pharynx cancer	8.86e-05	0.00133	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—CD79A—pharynx cancer	8.84e-05	0.00133	CbGpPWpGaD
Afatinib—ABL1—Integrated Pancreatic Cancer Pathway—EGFR—pharynx cancer	8.82e-05	0.00133	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—ADH7—pharynx cancer	8.75e-05	0.00132	CbGpPWpGaD
Afatinib—LCK—Signaling by ERBB4—EGFR—pharynx cancer	8.72e-05	0.00131	CbGpPWpGaD
Afatinib—LCK—Downstream signal transduction—EGFR—pharynx cancer	8.33e-05	0.00125	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CD79A—pharynx cancer	8.32e-05	0.00125	CbGpPWpGaD
Afatinib—LCK—Signaling by FGFR—EGFR—pharynx cancer	8.29e-05	0.00125	CbGpPWpGaD
Afatinib—LCK—Signaling by ERBB2—EGFR—pharynx cancer	8.24e-05	0.00124	CbGpPWpGaD
Afatinib—LCK—DAP12 signaling—EGFR—pharynx cancer	8.2e-05	0.00124	CbGpPWpGaD
Afatinib—IRAK1—Signaling by NGF—EGFR—pharynx cancer	8.16e-05	0.00123	CbGpPWpGaD
Afatinib—EGFR—Direct p53 effectors—TP53—pharynx cancer	8.11e-05	0.00122	CbGpPWpGaD
Afatinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—EGFR—pharynx cancer	8.09e-05	0.00122	CbGpPWpGaD
Afatinib—LCK—Signaling by FGFR in disease—EGFR—pharynx cancer	7.72e-05	0.00116	CbGpPWpGaD
Afatinib—LCK—DAP12 interactions—EGFR—pharynx cancer	7.72e-05	0.00116	CbGpPWpGaD
Afatinib—LCK—Fc epsilon receptor (FCERI) signaling—EGFR—pharynx cancer	7.72e-05	0.00116	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—ADH1B—pharynx cancer	7.67e-05	0.00115	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR—EGFR—pharynx cancer	7.65e-05	0.00115	CbGpPWpGaD
Afatinib—EGFR—Integrated Breast Cancer Pathway—TP53—pharynx cancer	7.64e-05	0.00115	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR in Cancer—EGFR—pharynx cancer	7.58e-05	0.00114	CbGpPWpGaD
Afatinib—LCK—Signaling by PDGF—EGFR—pharynx cancer	7.55e-05	0.00114	CbGpPWpGaD
Afatinib—ABL1—Integrated Pancreatic Cancer Pathway—TP53—pharynx cancer	7.41e-05	0.00111	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—B4GALT5—pharynx cancer	7.33e-05	0.0011	CbGpPWpGaD
Afatinib—ERBB2—Developmental Biology—EGFR—pharynx cancer	7.29e-05	0.0011	CbGpPWpGaD
Afatinib—LCK—B Cell Activation—EGFR—pharynx cancer	7.14e-05	0.00108	CbGpPWpGaD
Afatinib—EGFR—MAPK Signaling Pathway—TP53—pharynx cancer	7.01e-05	0.00106	CbGpPWpGaD
Afatinib—PHKG2—Disease—EGFR—pharynx cancer	6.98e-05	0.00105	CbGpPWpGaD
Afatinib—LCK—NGF signalling via TRKA from the plasma membrane—EGFR—pharynx cancer	6.84e-05	0.00103	CbGpPWpGaD
Afatinib—ABL1—Immune System—CD79A—pharynx cancer	6.51e-05	0.00098	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—EGFR—pharynx cancer	6.44e-05	0.000969	CbGpPWpGaD
Afatinib—ERBB2—Immune System—CDH1—pharynx cancer	6.41e-05	0.000965	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—EGFR—pharynx cancer	6.34e-05	0.000955	CbGpPWpGaD
Afatinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—pharynx cancer	6.33e-05	0.000953	CbGpPWpGaD
Afatinib—ERBB4—Immune System—CDH1—pharynx cancer	6.32e-05	0.000951	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—EGFR—pharynx cancer	6.18e-05	0.000931	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—EGFR—pharynx cancer	6.09e-05	0.000917	CbGpPWpGaD
Afatinib—BLK—Immune System—CDH1—pharynx cancer	6.08e-05	0.000915	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—EGFR—pharynx cancer	5.86e-05	0.000882	CbGpPWpGaD
Afatinib—ABL1—Axon guidance—EGFR—pharynx cancer	5.78e-05	0.00087	CbGpPWpGaD
Afatinib—EGFR—Immune System—CD79A—pharynx cancer	5.56e-05	0.000838	CbGpPWpGaD
Afatinib—LCK—Immune System—CD79A—pharynx cancer	5.36e-05	0.000807	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—EGFR—pharynx cancer	5.26e-05	0.000792	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CNDP2—pharynx cancer	5.23e-05	0.000787	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—CDH1—pharynx cancer	5.11e-05	0.000769	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—CDH1—pharynx cancer	4.92e-05	0.000741	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—pharynx cancer	4.85e-05	0.00073	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ADH7—pharynx cancer	4.73e-05	0.000712	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—EGFR—pharynx cancer	4.65e-05	0.000701	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CDH1—pharynx cancer	4.64e-05	0.000698	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ADH1B—pharynx cancer	4.15e-05	0.000624	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—EGFR—pharynx cancer	4.12e-05	0.000621	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—B4GALT5—pharynx cancer	3.96e-05	0.000597	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—pharynx cancer	3.8e-05	0.000573	CbGpPWpGaD
Afatinib—ERBB2—Immune System—EGFR—pharynx cancer	3.75e-05	0.000565	CbGpPWpGaD
Afatinib—ERBB4—Immune System—EGFR—pharynx cancer	3.69e-05	0.000556	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—EGFR—pharynx cancer	3.64e-05	0.000548	CbGpPWpGaD
Afatinib—ABL1—Immune System—CDH1—pharynx cancer	3.63e-05	0.000546	CbGpPWpGaD
Afatinib—BLK—Immune System—EGFR—pharynx cancer	3.55e-05	0.000535	CbGpPWpGaD
Afatinib—ERBB2—Disease—EGFR—pharynx cancer	3.46e-05	0.000521	CbGpPWpGaD
Afatinib—ERBB4—Disease—EGFR—pharynx cancer	3.41e-05	0.000513	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—TP53—pharynx cancer	3.4e-05	0.000511	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—pharynx cancer	3.19e-05	0.000481	CbGpPWpGaD
Afatinib—EGFR—Immune System—CDH1—pharynx cancer	3.1e-05	0.000467	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CCND1—pharynx cancer	3.09e-05	0.000465	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CCND1—pharynx cancer	3.04e-05	0.000458	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—EGFR—pharynx cancer	3e-05	0.000452	CbGpPWpGaD
Afatinib—LCK—Immune System—CDH1—pharynx cancer	2.99e-05	0.00045	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—EGFR—pharynx cancer	2.88e-05	0.000434	CbGpPWpGaD
Afatinib—LCK—Hemostasis—TP53—pharynx cancer	2.8e-05	0.000421	CbGpPWpGaD
Afatinib—IRAK1—Immune System—EGFR—pharynx cancer	2.71e-05	0.000408	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—EGFR—pharynx cancer	2.42e-05	0.000365	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—EGFR—pharynx cancer	2.39e-05	0.00036	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CCND1—pharynx cancer	2.23e-05	0.000336	CbGpPWpGaD
Afatinib—ABL1—Immune System—EGFR—pharynx cancer	2.12e-05	0.000319	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TP53—pharynx cancer	2.04e-05	0.000306	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TP53—pharynx cancer	2e-05	0.000302	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—EGFR—pharynx cancer	1.75e-05	0.000264	CbGpPWpGaD
Afatinib—LCK—Immune System—EGFR—pharynx cancer	1.75e-05	0.000263	CbGpPWpGaD
Afatinib—LCK—Disease—EGFR—pharynx cancer	1.61e-05	0.000243	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCND1—pharynx cancer	1.49e-05	0.000225	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TP53—pharynx cancer	1.47e-05	0.000222	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCND1—pharynx cancer	1.44e-05	0.000217	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—EGFR—pharynx cancer	1.13e-05	0.00017	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TP53—pharynx cancer	9.84e-06	0.000148	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TP53—pharynx cancer	9.48e-06	0.000143	CbGpPWpGaD
